Thu.Feb 29, 2024

article thumbnail

NCPA Pharmacy Ownership Workshop Empowers, Educates, and Inspires

Drug Topics

Three times each year, the National Community Pharmacists Association holds intensive workshops that drill down into the nitty gritty of pharmacy ownership.

98
article thumbnail

STAT+: This chemist’s last startup sold for $4 billion. Now investors have poured $173 million into her next act

STAT

Jean Cui, a former Pfizer chemist whose last company was sold to Bristol Myers Squibb for $4 billion, has raised $173 million from a coalition of top biotech investors for her new company, BlossomHill Therapeutics. BlossomHill is preparing to start human clinical studies of potential medicines that could someday treat blood cancer and lung cancer. It announced Thursday that it has raised $100 million from firms including Colt Ventures, Cormorant Asset Management, and OrbiMed.

70
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Investigational GLP-1 Medication Found to Reduce Body Weight

Pharmacy Times

VK2735, a dual agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide, is being developed as a potential treatment for various metabolic disorders.

65
article thumbnail

STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials

STAT

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions. Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Compliance and Stewardship: Waste Reduction and Cost Savings

Pharmacy Times

Health care providers discuss how prefilled syringes reduce diversion risks, enhance waste management, and offer cost-effective solutions, ensuring compliance with regulations.

65
article thumbnail

Palatin pummelled as dry eye therapy underwhelms in phase 3

pharmaphorum

Palatin Technologies’ therapy for dry eye disease (DED) missed its primary endpoints in a phase 3 trial, knocking investor confidence as it tries to chart a way forward.

64

More Trending

article thumbnail

STAT+: Pfizer is about to make a big push in cancer. Will investors listen?

STAT

Pfizer has a big problem. The drug giant hopes that new drugs to treat cancer are the solution. Shares in the drugmaker fell 44% last year, and it now has a market capitalization of only $150 billion — a quarter that of Eli Lilly and half that of longtime rival Merck. In March of last year the company announced that it would spend $43 billion to buy Seagen , a maker of a hot category of oncology medicines called antibody-drug conjugates.

58
article thumbnail

Analysis Identifies International Treatment Outcomes, Patterns in Individuals With NDMM

Pharmacy Times

The authors found that overall survival in patients with newly diagnosed multiple myeloma was longest for those receiving first-line autologous stem cell transplantation.

65
article thumbnail

GI-targeted ROCK inhibitor for fibrostenotic Crohn’s disease in phase 1 study

Outsourcing Pharma

Yesterday, (February 28), a clinical-stage biotechnology company, Redx, announced that the first participant has been dosed in a phase 1 clinical trial for RXC008.

64
article thumbnail

Insights and Strategies Into Optimizing Opioid Management

Pharmacy Times

Experts review comprehensive strategies to enhance patient safety and responsible opioid management across assessment, monitoring, alternatives, and collaboration.

65
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Virta Health champions its nutrition therapy as an effective GLP-1 off-ramp. Here's why

Fierce Healthcare

Telemedicine clinic Virta Health believes its members can achieve significant and sustained improvement in weight loss, even if a patient has stopped taking a GLP-1 drug, a newly released paper in | A new study in Diabetes Therapy from Virta Health says the company's carbohydrate restricted nutrition therapy allows patients who no longer want a GLP-1 prescription to still keep the weight off.

59
article thumbnail

Cardinal Health Annual Research Report Examines Milestone Year in Biosimilars

Pharmacy Times

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.

65
article thumbnail

Lifebit unlocks the potential of diverse data to accelerate pharmaceutical R&D

Outsourcing Pharma

Lifebit, a progressive biomedical data technology and services company, has reached a huge milestone, boasting a catalog of 100 million patients in its multi-omic and health data repository.

59
article thumbnail

Longevity Science Is Trying to Strike A Balance Between Innovation and Traditional Health Care

Pharmacy Times

There is a growing number of technologies, processes, and treatments being discovered in the quest to extend life.

73
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance

Pharmafile

Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug (IND) application to assess SPR206 in a phase 2 clinical study. The candidate is a novel, intravenously (IV) administered next-generation polymyxin antibiotic intended to be used for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia […] The post Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance appeared f

FDA 59
article thumbnail

STAT+: Biotech launches with $82 million for Parkinson’s cell therapy

STAT

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.  Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and pension fund Alaska Permanent Fund Corp.

55
article thumbnail

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

Pharmafile

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The drug is a first-in-class oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris (eculizumab) for the […] The post AstraZeneca’s Voydeya recommended for approval in EU by CHMP appeared first on Pharmafile.

59
article thumbnail

Clinigen educates on early access to rare disease therapies

pharmaphorum

On Rare Disease Day, Clinigen has launched a campaign to try to encourage doctors and patients to explore how they can get early access to investigational therapies.

59
article thumbnail

Novel Chemotherapy Method Could Decrease Lung Cancer Tumor Size

Pharmacy Times

The findings suggest that the CAR T-cell membrane-coated PLGA nanoparticles reduced tumor size after 1 dose of treatment.

article thumbnail

STAT+: Pharmalittle: We’re reading about White House eyeing PBMs, Pfizer CEO’s frustrations, and more

STAT

Top of the morning to you, and a fine one it is. Cold winds and overcast skies will not deter us from celebrating another brand new day here on the Pharmalot campus, where the official mascots are hunting for creatures and a parade of driving machines is passing near by. As for us, we are engaged in the usual ritual — brewing cups of stimulation.

article thumbnail

Company Profile: 60 Seconds

pharmaphorum

Learn more about Marcus West and his company, 60 Seconds, specialising in coaching services to help individuals and teams reach their full potential.

59
article thumbnail

Flu vaccine offering decent levels of protection this winter, new data show

STAT

Flu vaccine appears to be offering reasonable levels of protection this winter, with particularly strong levels in children, new data from the Centers for Disease Control and Prevention suggest. The vaccine effectiveness estimates, which showed unusually robust protection of children against influenza B viruses but more modest protection of people aged 65 and older against influenza A viruses, were presented Wednesday at a meeting of the CDC’s expert vaccine panel, the Advisory Committee

article thumbnail

Tislelizumab receives positive CHMP opinion for three NSCLC indications

Hospital Pharmacy Europe

The monoclonal antibody tislelizumab (brand name Tevimbra) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of non-small cell lung cancer (NSCLC) across three indications, its manufacturer BeiGene has announced. Tislelizumab has been recommended by the CHMP for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of adult patients with squamous NSCLC who

article thumbnail

STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk

STAT

LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a week, indefinitely. But what if they could be taken once a year instead, like a vaccine? That’s a question that Novo Nordisk, the pharma company behind Wegovy, is exploring as it faces increased competition from other drugmakers aiming to develop similar GLP-1-based treatments for obesity.

article thumbnail

Olive oil-derived drug shows early promise for patients with glioblastoma

Hospital Pharmacy Europe

A first-in-class drug derived from olive oil has shown early promise in patients with an advanced form of brain cancer in a new trial led by The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research. Idroxioleic acid (2-OHOA), is a synthetic lipid derived from olive oil, comes in a small sachet and is taken with water three times a day.

article thumbnail

Q&A: A biotech VC leader shares her next big bets

STAT

Kristina Burow has a well-trained eye. That’s true of her work at ARCH Venture Partners, one of the drug industry’s largest and most active investment firms, and also outside of work — those who know her say Burow is a deadly shot with a pistol. Burow is a managing director at ARCH, where she has been influential in building bold and well-capitalized startups.

53
article thumbnail

Innovative combination treatment significantly improves survival in pleural mesothelioma

Hospital Pharmacy Europe

Adding an arginine-depleting agent to chemotherapy extends survival for patients with advanced non-epithelial pleural mesothelioma, a randomised controlled trial suggests. The ATOMIC-Meso trial is the continuation of 20 years of research at Barts Cancer Institute at Queen Mary University of London, that began with the discovery that malignant mesothelioma cells lack the argininosuccinate synthetase 1 (ASS1) protein, which enables cells to manufacture their own arginine.

article thumbnail

The next act for a biotech rainmaker

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up to get our biotech newsletter in your inbox. Hello, everyone. Damian here with an explanation of the latest trend in biotech financing, a big idea in oncology, and Novo Nordisk’s plans to make Wegovy obsolete.

article thumbnail

GSK avoids trial with another Zantac settlement in California

Fierce Pharma

For the second time in four weeks, GSK has settled a personal injury lawsuit in California sta | For the second time in four weeks, GSK has settled a personal injury lawsuit in California state court over the heartburn drug Zantac. The company revealed the dismissal of the case and the agreement in a release Thursday.

52
article thumbnail

Indena’s CDMO services: Health is a joint project

Pharmaceutical Technology

For Indena, the leading company dedicated to the identification, development and production of high-quality active principles derived from plants, custom services have been a key area of expertise for some time now.

article thumbnail

In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials

Fierce Pharma

Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. | Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional.

52
article thumbnail

The health risks of ultra-processed foods (UPFs) are worse than we think

Pharmaceutical Technology

Research published by the British Medical Journal on 28 February 2024, has found that ultra-processed foods (UPFs), including cereals, chocolate bars, and ready meals, are linked to 32 negative health outcomes.

52
article thumbnail

After setting out on its own, Sandoz inks $265M deal to resolve 'legacy' price-fixing lawsuit

Fierce Pharma

Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in | Sandoz, after inking a new settlement in a price-fixing case inherited from its former parent Novartis, says it’s taken an encouraging step on its quest to leave “allegations of legacy conduct” in the past.

52
article thumbnail

'Dozens and dozens' of data analytics projects drive $100M+ in savings, revenue gains for UnityPoint Health

Fierce Healthcare

Long-term commitment and a willingness to stomach both upfront and last-mile burdens are the price of admission for millions in analytics-based cost savings and revenue enhancements. | The nonprofit health system partnered with Health Catalyst on eight years of performance improvement initiatives targeting length of stay, care management, ED utilization and other costly focus areas.

52